Eisenmenger's syndrome: Current management

Progress in Cardiovascular Diseases

Volumn 45, Issue 2, 2002, Pages 129-138

  Berman, Erika Berman ^a   Barst, Robyn J ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOREX; ANOREXIGENIC AGENT; ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; DEXFENFLURAMINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ELASTASE INHIBITOR; FENFLURAMINE; HORMONE; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; OXYGEN; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; VASODILATOR AGENT; WARFARIN;

ANTICOAGULATION; BLALOCK HANLON OPERATION; CONGENITAL HEART MALFORMATION; DIAGNOSTIC TEST; DISEASE COURSE; EISENMENGER COMPLEX; HEART LUNG TRANSPLANTATION; HUMAN; LUNG ARTERY PRESSURE; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; OXYGEN THERAPY; PATHOPHYSIOLOGY; PHLEBOTOMY; PHYSICAL EXAMINATION; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SURGICAL TECHNIQUE; SYMPTOMATOLOGY;

EID: 0036710067     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1053/pcad.2002.127492     Document Type: Article

References (36)

1. Friedman WF (ed): Proceedings of the National Heart, Lung, and Blood Institute Pediatric Cardiology Workshop: Pulmonary Hypertension, Pediatric Research, vol 20. 1986: pp 811-824
2. Eisenmenger V: Die angeborenen defecte der kammerscheidewand des herzen. Z Klin Med Suppl 32:1-28, 1897
3. Wood P: The Eisenmenger syndrome. Br Med J 2:755, 1958
4. Keck BM, Bennett LE, Rosendale J, et al: Worldwide thoracic organ transplantation: A report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clin Transpl 35-49, 1999
5. Hopkins WE, Ochoa LL, Richardson GW, et al: Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 15:100-105, 1996
6. Kidd L, Driscoll DJ, Gersony WM, et al: Second natural history study of congenital heart efects. Circulation 87:138-51, 1993 (suppl I)
7. Clarkson PM, Frye RL, DuShane JW, et al: Prognosis for patients with ventricular septal defect and severe pulmonary vascular obstructive disease. Circulation 38:129, 1968
8. Rubin LJ, Rich S (eds): Primary Pulmonary Hypertension. Lung Biology in Health and Disease, vol 99. New York, Marcel Dekker, pp. 27,34, 1977
9. Haworth SG: Pulmonary vascular disease in ventricular septal defect: Structural and functional correlations in lung biopsies from 85 patients, with outcome of intracardiac repair. J Pathol 152:157-168, 1987
10. Fullerton DA, Mitchell MB, Jones DN, et al: Pulmonary vasomotor dysfunction is produced with chronically high pulmonary blood flow. J Thorac Cardiovasc Surg 111:190-197, 1996
11. Somerville J: How to manage the Eisenmenger syndrome. Int J Cardiol 63:1-8, 1998
12. Kerstein D, Levy PS, Hsu DT, et al: Blade balloon atrial septostomy improves survival in patients with severe primary pulmonary hypertension. Circulation 91:2028-2035, 1995
13. Sandoval J, Gaspar J, Pulido T, et al: Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 32:297-304, 1998
14. Hausknecht MJ, Sims RE, Nihill MR, et al: Successful palliation of primary pulmonary hypertension by atrial septostomy. Am J Cardiol 65:1045-1046, 1990
15. Hopkins WE, Ochou LL, Richardson GW, et al: Hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 14:536, 1995
16. Sandoval J, Rothman A, Pulido T: Atrial septostomy for pulmonary hypertension. Clin Chest Med 22:547-560, 2001
17. Barst RJ: Recent advances in the treatment of pediatric pulmonary artery hypertension. Pediatric Clin North Am 46:2, 1999
18. Boyer JJ, Busst CM, Denison DM, et al: Effect of long-term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J 55:385-390, 1985
19. Rich S, Seidlitz M, Dodin E, et al: The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114:787-792, 1998
20. Rosove MH, Perloff JK, Hocking WG, et al: Chronic hypoxaemia and decompensated erythrocytosis in cyanotic congenital heart disease. Lancet 2:313, 1986
21. Perloff JK: Systemic complications of cyanosis in adults with congenital heart disease: Hematologic derangements, renal function, and urate metabolism. Cardiol Clin 11:689-699, 1993
22. Berman-Rosenzweig E, Kerstein D, Barst RJ: Chronic prostacyclin therapy for pulmonary hypertension with associated congenital heart defects. Circulation 99:1858-1865, 1999
23. Rich S, Kaufmann E, Levy P: The effects of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76-81, 1992
24. Berman-Rosenzweig E, Maislin G, Kerstein D, et al: Acute vasodilator response and survival in patients with pulmonary vascular disease and congenital heart defects. Am J Respir Crit Care Med 161:A423, 2000
25. Rosovec A, Montanes P, Oakley C: Factors that influence the outcome of primary pulmonary hypertension. Br Heart J 55:449-458, 1986
26. Young D, Mark H: Fate of the patient with Eisenmenger's syndrome. Am J Cardiol 28:658-669, 1971
27. Trulock EP: Lung transplantation for primary pulmonary hypertension. Clin Chest Med 22:583-593, 2001
28. Pasque MK, Trulock EP, Cooper JD, et al: Single lung transplantation for pulmonary hypertension: Single institution experience in 34 patients. Circulation 92:2252-2258, 1995
29. Gurtner HP: Pulmonary hypertension, plexogenic pulmonary arteriopathy and the appetite depressant drug aminorex: Post or propter? Bull Eur Physiopathol Respir 15:897-923, 1979
30. Greiser E: Epidemiologische untersuchungen zum zusammenhang zwischen appetitzueglere innahme und primaer vasculaer pulmonaler hypertonie. Internist 14:437-442, 1973
31. Douglas JG, Munro JF, Kitchin AH, et al: Pulmonary hypertension and fenfluramine. Br Med J 283:881-883, 1981
32. Roche N, Labrune S, Braun JM, et al: Pulmonary hypertension and dexfenfluramine. Lancet 339:436-437, 1992 (letter)
33. Brenot F, Herve P, Petitpretz P, et al: Primary pulmonary hypertension and fenfluramine use. Br Heart J 70:537-541, 1993
34. Deng Z, Morse JH, Slager SL, et al: Familial primary pulmonary hypertension (gene PPH 1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67:737-744, 2000
35. Nichols WC, Koller DL, Slovis B, et al: Localization of the gene for familial PPH to chromosome 2q31-32. Nat Genet 15:277-280, 1997
36. Morse JH, Jones AC, Barst RJ, et al: Mapping of familial primary pulmonary hypertension locus (PPH 1) to chromosome 2q31-32. Circulation 95:2603-2606, 1997